A Diverse and Experienced Board

Next Science's Board of Directors has extensive governance and operating experience. Collectively they have decades of experience in the life sciences industry with a focus on novel technology commercialization. Working closely with the Leadership Team they are focused on driving Next Science forward and bringing Next Science's novel Xbio technology to market.

George Savvides AM

Chair

George has 30 years of experience in the Australian & New Zealand healthcare sector. He was CEO of two successful IPO listings on the ASX, being Sigma in 1999 and Medibank Private in 2014. He served as Medibank CEO for 14 years.
George served as Chair of Kings Consolidated Group Pty Ltd (2016 to 2018) and Macquarie University Hospital (2016 to 2018) and retired as Chair of World Vision Australia after 18 years of service in February 2018. He was a board member of the International Federation of Health Plans for 10 years including a period as Deputy President, retiring in 2016. In early 2020, George was made a Member of the Order of Australia (AM) for significant service to the community, charitable groups and business. George currently serves as Non-Executive Chair of the public broadcaster SBS having been appointed a Non-Executive Director in 2017 and Chair in 2020. He is also a Non-Executive Director of IAG (since 2019) and NZX listed Ryman Healthcare, a large residential aged care provider in New Zealand (since 2013).

Judith Mitchell

Managing Director

Judith Mitchell joined Next Science as CEO in August 2017. Previously Ms. Mitchell was President, DePuy Synthes Asia Pacific, the Orthopedics Division of J&J, holding the same role at Synthes GmbH prior to acquisition. Prior to that, Ms. Mitchell held various executive management roles at Cochlear and GE.

Bruce Hancox

Non-Executive Director

Bruce has over 35 years of corporate experience across a broad spectrum of commerce, including 16 years with Brierley Investments Limited in New Zealand. He held a number of senior roles at Brierley Investments as general manager and chair and served on the board of a number of their subsidiaries in New Zealand, Australia and the US.
Bruce has been a financial advisor to interests of Mr Langley Walker since 2008. He serves as a director of investments and wealth management at Walker Corporation Pty Ltd and works with the Walker group of companies to pursue investment opportunities outside the property market.

Dan Spira

Non-Executive Director

Bruce has over 35 years of corporate experience across a broad spectrum of commerce, including 16 years with Brierley Investments Limited in New Zealand. He held a number of senior roles at Brierley Investments as general manager and chair and served on the board of a number of their subsidiaries in New Zealand, Australia and the US.
Bruce has been a financial advisor to interests of Mr Langley Walker since 2008. He serves as a director of investments and wealth management at Walker Corporation Pty Ltd and works with the Walker group of companies to pursue investment opportunities outside the property market.

Aileen Stockburger

Non-Executive Director

Prior to joining Next Science, Aileen was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group’s merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. She led Johnson & Johnson’s efforts to acquire Synthes for approximately $21 billion, Johnson & Johnson’s largest medical device acquisition. She also led the efforts to divest the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also involved in numerous other M&A transactions including Pfizer Consumer Healthcare (US$16.5 billion), Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena. Aileen is a Non-Executive Director of Microbot Medical Inc. (NASDAQ: MBOT)

Professor Mark Compton AM

Non-Executive Director

Mark is Lord Prior of the International Order of St John and Chair of the Board of Trustees of St John International. Mark is Chair of Sonic Healthcare Limited (ASX: SHL), a global medical diagnostics and healthcare organisation which is a Top 50 ASX listed entity. He is also Chair of St Luke’s Care Limited, a not for profit health and aged care organisation and Chair of Integrated Clinical Oncology Network Pty Ltd trading as Icon Cancer Centre. Mark has held various CEO and managing director roles, including at St Luke’s Care Limited, Immune System Therapeutics Limited, Royal Flying Doctor Service of Australia, SciGen Limited and Alpha Healthcare Limited. He is an Adjunct Professor at Macquarie University in healthcare leadership and management (since 2012) and in 2010 was appointed a Member of the Order of Australia (AM) for his services to healthcare.

In the News

Learn about the latest news and events from Next Science and its partners.